Want to see IN:NECLIFE full AI Analyst Report?
NECLIFE Stock Chart & Stats
₹10.30
-₹0.06(-0.58%)
At close: 4:00 PM EDT
₹10.30
-₹0.06(-0.58%)
Day’s Range― - ―
52-Week Range₹9.20 - ₹22.49
Previous CloseN/A
Volume4.76K
Average Volume (3M)18.31K
Market Cap
₹2.15B
Enterprise Value₹619.87M
Total Cash (Recent Filing)₹1.25B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield20.72%
Share Statistics
EPS (TTM)-11.38
Shares Outstanding194,260,970
10 Day Avg. Volume21,045
30 Day Avg. Volume18,309
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)97.56
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical OperationsExposure to APIs, finished dosages, and contract manufacturing or research gives Nectar Lifesciences multiple pharmaceutical revenue channels. This breadth can support customer diversification and allow the company to participate across different stages of the value chain over the next several quarters.
Historically Positive Cash FlowPositive operating and free cash flow across FY2022-FY2025 shows the business has previously converted operations into cash and was not structurally cash-negative throughout the period. Although FY2026 weakened sharply, this history provides evidence of prior cash-generation capability.
Moderate Historical LeverageHistorically moderate leverage and a positive equity base provide a stronger starting point than a highly indebted balance sheet. This can preserve some financial flexibility for operations and recovery, even though deteriorating performance has recently raised concerns about balance-sheet durability.
Bears Say
FY2026 Revenue CollapseRevenue falling to zero represents a severe disruption to the company’s commercial operations and makes near-term earnings visibility exceptionally weak. If sustained, the collapse would undermine scale benefits, customer continuity, and the ability to support fixed operating costs over the coming quarters.
Severe Cash BurnLarge negative operating and free cash flow indicate that the company is consuming cash rather than funding itself through operations. Persistent burn could increase reliance on external funding, constrain investment in pharmaceutical activities, and elevate liquidity risk during the recovery period.
Unstable ProfitabilityThe swing from a modest FY2024 recovery to meaningful FY2025 losses and very large FY2026 losses demonstrates poor earnings consistency. Unstable profitability weakens internal funding capacity, complicates planning, and makes sustainable margins difficult to establish over the next several quarters.
Nectar Lifesciences Ltd. News
NECLIFE FAQ
What was Nectar Lifesciences Ltd.’s price range in the past 12 months?
Nectar Lifesciences Ltd. lowest stock price was ₹9.20 and its highest was ₹22.49 in the past 12 months.
What is Nectar Lifesciences Ltd.’s market cap?
Nectar Lifesciences Ltd.’s market cap is ₹2.15B.
When is Nectar Lifesciences Ltd.’s upcoming earnings report date?
Nectar Lifesciences Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Nectar Lifesciences Ltd.’s earnings last quarter?
Nectar Lifesciences Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.793 earnings per share for the quarter.
Is Nectar Lifesciences Ltd. overvalued?
According to Wall Street analysts Nectar Lifesciences Ltd.’s price is currently Overvalued.
Does Nectar Lifesciences Ltd. pay dividends?
Nectar Lifesciences Ltd. pays a Annually dividend of ₹4.319 which represents an annual dividend yield of 20.72%. See more information on Nectar Lifesciences Ltd. dividends here
What is Nectar Lifesciences Ltd.’s EPS estimate?
Nectar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nectar Lifesciences Ltd. have?
Nectar Lifesciences Ltd. has 194,260,970 shares outstanding.
What happened to Nectar Lifesciences Ltd.’s price movement after its last earnings report?
Nectar Lifesciences Ltd. reported an EPS of -₹0.793 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nectar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in IN:NECLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nectar Lifesciences Ltd.
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―